KBC Group’s Recursion Pharmaceuticals RXRX Stock Holding History

KBC Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45K	Hold	12,307	–	–	﹤0.01%	1737
2026 Q1	$38K	Hold	12,307	–	–	﹤0.01%	1744
2025 Q4	$50K	Hold	12,307	–	–	﹤0.01%	1643
2025 Q3	$60K	Hold	12,307	–	–	﹤0.01%	1580
2025 Q2	$62K	Hold	12,307	–	–	﹤0.01%	1486
2025 Q1	$65K	Hold	12,307	–	–	﹤0.01%	1711
2024 Q4	$83K	Buy	12,307 +4,705	+62%	+$31.6K	﹤0.01%	1665
2024 Q3	$50K	Buy	7,602 +3,377	+80%	+$24.2K	﹤0.01%	1710
2024 Q2	$32K	Hold	4,225	–	–	﹤0.01%	1807
2024 Q1	$42K	Hold	4,225	–	–	﹤0.01%	1644
2023 Q4	$42K	Hold	4,225	–	–	﹤0.01%	1651
2023 Q3	$32K	Buy	+4,225	New	+$42.1K	﹤0.01%	1759

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

KBC Group's RXRX Position: Q2 2026 in Review

KBC Group held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 12,307 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

KBC Group first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $83K in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

KBC Group held 12,307 shares of Recursion Pharmaceuticals worth $45K as of Q2 2026.
KBC Group left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1737 holding.
KBC Group first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
KBC Group's Recursion Pharmaceuticals position peaked at $83K in Q4 2024.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.